162 related articles for article (PubMed ID: 23979447)
1. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications.
Thorén FB; Anderson H; Strannegård Ö
Cancer Immunol Immunother; 2013 Oct; 62(10):1547-51. PubMed ID: 23979447
[TBL] [Abstract][Full Text] [Related]
2. Improved endpoints for cancer immunotherapy trials.
Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
[TBL] [Abstract][Full Text] [Related]
3. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
4. A practical divergence measure for survival distributions that can be estimated from Kaplan-Meier curves.
Cox TF; Czanner G
Stat Med; 2016 Jun; 35(14):2406-21. PubMed ID: 26842429
[TBL] [Abstract][Full Text] [Related]
5. Implications of survival curve slopes on the interpretation of adjuvant therapy results.
Eriguchi M; Mathé G
Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):93-7. PubMed ID: 2743534
[TBL] [Abstract][Full Text] [Related]
6. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
9. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
Ding X; Wu J
Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
[TBL] [Abstract][Full Text] [Related]
10. Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.
Mick R; Chen TT
Cancer Immunol Res; 2015 Dec; 3(12):1292-8. PubMed ID: 26644449
[TBL] [Abstract][Full Text] [Related]
11. On assessing survival benefit of immunotherapy using long-term restricted mean survival time.
Horiguchi M; Tian L; Uno H
Stat Med; 2023 Apr; 42(8):1139-1155. PubMed ID: 36653933
[TBL] [Abstract][Full Text] [Related]
12. Gaining power and precision by using model-based weights in the analysis of late stage cancer trials with substantial treatment switching.
Bowden J; Seaman S; Huang X; White IR
Stat Med; 2016 Apr; 35(9):1423-40. PubMed ID: 26576494
[TBL] [Abstract][Full Text] [Related]
13. New survival curve model for comparison of adjuvant therapy of malignant diseases.
Eriguchi M; Mathé G
Biomed Pharmacother; 1986; 40(4):143-7. PubMed ID: 3790708
[TBL] [Abstract][Full Text] [Related]
14. Designing cancer immunotherapy trials with random treatment time-lag effect.
Xu Z; Park Y; Zhen B; Zhu B
Stat Med; 2018 Dec; 37(30):4589-4609. PubMed ID: 30203592
[TBL] [Abstract][Full Text] [Related]
15. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy trial design with delayed treatment effect.
Wu J; Wei J
Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
[TBL] [Abstract][Full Text] [Related]
17. Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.
Xu Z; Park Y; Liu K; Zhu B
J Hematol Oncol; 2020 Mar; 13(1):20. PubMed ID: 32171307
[TBL] [Abstract][Full Text] [Related]
18. Insights for Quantifying the Long-Term Benefit of Immunotherapy Using Quantile Regression.
Mboup B; Le Tourneau C; Latouche A
JCO Precis Oncol; 2021 Nov; 5():173-176. PubMed ID: 34994596
[TBL] [Abstract][Full Text] [Related]
19. Evolution of end points for cancer immunotherapy trials.
Hoos A
Ann Oncol; 2012 Sep; 23 Suppl 8():viii47-52. PubMed ID: 22918928
[TBL] [Abstract][Full Text] [Related]
20. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]